Trials / Completed
CompletedNCT03486379
Folfiri as Third Line of Treatment
FOLFIRI as a Second-line Therapy in Patients With Docetaxel-pretreated Gastric Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 26 (actual)
- Sponsor
- IRCCS Cancer Referral Center of Basilicata · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to investigate the activity of Folfiri as Third line of treatment in mGC progressed after ramuciramb-based second line.
Conditions
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2017-09-30
- Completion
- 2018-03-23
- First posted
- 2018-04-03
- Last updated
- 2018-04-03
Source: ClinicalTrials.gov record NCT03486379. Inclusion in this directory is not an endorsement.